For instance, in Chronic Myeloid Leukemia (CML), tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib represent a first-line non-chemotherapeutic approach, yet resistance to these agents, often involving P-gp, remains a clinical challenge [55,56]. This evidence concerns the gene PGP and chronic myelogenous leukemia, BCR-ABL1 positive.